Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Director Floyd F. Petersen Sells 3,000 Shares of Stock

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Director Floyd F. Petersen sold 3,000 shares of Amphastar Pharmaceuticals stock in a transaction on Thursday, September 5th. The shares were sold at an average price of $46.47, for a total transaction of $139,410.00. Following the completion of the sale, the director now owns 75,409 shares in the company, valued at $3,504,256.23. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Amphastar Pharmaceuticals Stock Performance

Shares of AMPH stock opened at $45.38 on Friday. The company has a market capitalization of $2.22 billion, a price-to-earnings ratio of 15.70, a PEG ratio of 0.92 and a beta of 0.79. The company has a debt-to-equity ratio of 0.82, a quick ratio of 2.63 and a current ratio of 3.52. The company has a 50-day simple moving average of $42.58 and a 200 day simple moving average of $43.00. Amphastar Pharmaceuticals, Inc. has a 52 week low of $36.56 and a 52 week high of $65.92.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last announced its earnings results on Wednesday, August 7th. The company reported $0.85 EPS for the quarter, topping the consensus estimate of $0.75 by $0.10. The business had revenue of $182.39 million during the quarter, compared to the consensus estimate of $171.29 million. Amphastar Pharmaceuticals had a net margin of 23.36% and a return on equity of 29.79%. On average, sell-side analysts predict that Amphastar Pharmaceuticals, Inc. will post 3.71 earnings per share for the current year.

Analyst Ratings Changes

A number of research analysts have recently commented on AMPH shares. Needham & Company LLC reissued a “hold” rating on shares of Amphastar Pharmaceuticals in a research report on Thursday, August 8th. StockNews.com raised shares of Amphastar Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Monday, September 2nd. Finally, Piper Sandler decreased their price objective on shares of Amphastar Pharmaceuticals from $71.00 to $66.00 and set an “overweight” rating for the company in a research report on Thursday, August 8th. Two investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $63.00.

Institutional Trading of Amphastar Pharmaceuticals

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Cim LLC boosted its holdings in shares of Amphastar Pharmaceuticals by 7.5% during the 2nd quarter. Cim LLC now owns 10,016 shares of the company’s stock worth $401,000 after buying an additional 701 shares during the period. Sanctuary Advisors LLC bought a new stake in shares of Amphastar Pharmaceuticals during the 2nd quarter worth about $388,000. Aurora Investment Counsel bought a new stake in shares of Amphastar Pharmaceuticals during the 2nd quarter worth about $2,179,000. Invst LLC boosted its holdings in shares of Amphastar Pharmaceuticals by 101.3% during the 2nd quarter. Invst LLC now owns 11,638 shares of the company’s stock worth $448,000 after buying an additional 5,857 shares during the period. Finally, The Manufacturers Life Insurance Company boosted its holdings in Amphastar Pharmaceuticals by 4.5% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 22,246 shares of the company’s stock valued at $890,000 after purchasing an additional 954 shares during the period. Institutional investors own 65.09% of the company’s stock.

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.